Cargando…
Initial Clinical Experience of RP5063 Following Single Doses in Normal Healthy Volunteers and Multiple Doses in Patients with Stable Schizophrenia
RP5063 is a multimodal dopamine (D)‐serotonin (5‐HT) stabilizer with a high affinity for D(2/3/4) and 5‐HT(1A/2A/2B/7) receptors and moderate affinity for the serotonin transporter. Single‐dose (10 and 15 mg fasting, 15 mg fed) safety in healthy volunteers and multiple‐dose (10, 20, 50, and 100 mg f...
Autores principales: | Cantillon, Marc, Ings, Robert, Bhat, Laxminarayan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039200/ https://www.ncbi.nlm.nih.gov/pubmed/29637739 http://dx.doi.org/10.1111/cts.12545 |
Ejemplares similares
-
Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients
por: Cantillon, Marc, et al.
Publicado: (2017) -
A Population Pharmacokinetic and Pharmacodynamic Analysis of RP5063 Phase 2 Study Data in Patients with Schizophrenia or Schizoaffective Disorder
por: Cantillon, Marc, et al.
Publicado: (2018) -
Single-dose and multiple-dose pharmacokinetics of zaltoprofen after oral administration in healthy Chinese volunteers
por: Li, Lingjun, et al.
Publicado: (2011) -
Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers
por: Jiang, Ji, et al.
Publicado: (2014) -
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
por: Wang, Shining, et al.
Publicado: (2022)